Tyra Biosciences director granted 13,160 stock options

Tyra Biosciences director Susan Moran received a grant of stock options covering 13,160 shares of common stock.

Rhea-AI Filing Summary

Tyra Biosciences director Susan Moran received a grant of stock options covering 13,160 shares of common stock. The options have an exercise price of $32.68 per share and were granted under the company’s Non-Employee Director Compensation Program as equity compensation.

The options vest over time: 1/12 of the 13,160 shares vest monthly after the May 28, 2026 grant date. If the next annual stockholder meeting occurs before the first anniversary of the grant, any remaining unvested options vest at that meeting, provided she continues serving the company. Following this grant, she holds 13,160 options directly.

Insider Trade Summary

Grant/Award: 13,160 shares

Grant/Award 1 txn

Insider Moran Susan

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	13,160	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 13,160 contracts (Direct)

Footnotes (1)

1. F1. The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

Key Figures

Options granted: 13,160 options Exercise price: $32.68 per share Underlying shares: 13,160 shares +3 more

6 metrics

Options granted 13,160 options Stock Option (Right to Buy) grant on May 28, 2026

Exercise price $32.68 per share Exercise price of options for Tyra common stock

Underlying shares 13,160 shares Underlying common stock for the option grant

Total options after grant 13,160 options Total derivative holdings following this transaction

Expiration date May 27, 2036 Option expiration for this grant

Vesting cadence 1/12 monthly Monthly vesting installments after May 28, 2026

Key Terms

Stock Option (Right to Buy), Non-Employee Director Compensation Program, vesting, exercise price

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Non-Employee Director Compensation Program financial

"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program."

vesting financial

"1/12th of the total number of shares of common stock subject to the option vest monthly"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

exercise price financial

"conversion_or_exercise_price: 32.6800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

What did Tyra Biosciences (TYRA) director Susan Moran report on this Form 4?

Susan Moran reported receiving a grant of stock options for 13,160 shares of Tyra Biosciences common stock. These options are compensation under the Non-Employee Director Compensation Program and give her the right to buy shares at a fixed exercise price if they vest and are exercised.

What is the exercise price of Susan Moran’s Tyra Biosciences (TYRA) stock options?

The stock options granted to Susan Moran have an exercise price of $32.68 per share. This is the price she would pay to purchase each share if she exercises the options after they have vested, regardless of the market price at that time.

How do Susan Moran’s Tyra Biosciences (TYRA) stock options vest over time?

The 13,160 stock options vest in monthly installments, with 1/12 of the total vesting each month after the May 28, 2026 grant date. This creates a roughly one-year vesting schedule, rewarding continued board service throughout the vesting period.

What happens to unvested Tyra Biosciences (TYRA) options if the annual meeting is held early?

If Tyra Biosciences holds its next annual stockholder meeting before the first anniversary of the May 28, 2026 grant, any remaining unvested options will fully vest on the meeting date. This accelerated vesting requires Susan Moran’s continuous service through each vesting date.

How many Tyra Biosciences (TYRA) options does Susan Moran hold after this grant?

After this transaction, Susan Moran holds 13,160 stock options directly. All of these options were granted in this award and relate to Tyra Biosciences common stock, subject to the specified vesting schedule and the $32.68 per share exercise price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/01/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moran Susan

(Last) (First) (Middle)

C/O TYRA BIOSCIENCES, INC.

2656 STATE STREET

(Street)

CARLSBAD CALIFORNIA 92008

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tyra Biosciences, Inc. [ TYRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$32.68	05/28/2026		A		13,160		(1)	05/27/2036	Common Stock	13,160	$0	13,160	D

Explanation of Responses:

1. The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

	/s/ Ali D. Fawaz, Attorney-in-Fact	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)